Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms
Alicia Arenas Cortés(Hospital Universitario 12 De Octubre), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Alicia Robles, María Linares(Universidad Complutense de Madrid), Pilar Hernández-Campo, Inmaculada Rapado(Wellcome Sanger Institute), Rosa Ayala(Hospital Universitario 12 De Octubre), Miguel Gallardo(Spanish National Cancer Research Centre), Julián Gorrochategui, María Luz Morales(Research Institute Hospital 12 de Octubre), Joan Ballesteros, Daniel Primo
Cited by 9
Related Papers
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523